endocrinology
Type 1 diabetes

Immunotherapy delays onset of type 1 diabetes by two years


Teplizumab can delay the onset of type 1 diabetes (T1D) for about two years in children and young adults at very high risk of developing the disease. The phase 2 international clinical trial involving Australian researchers comprised 76 children and young adults with a family history of T1D, at least two diabetes-related autoantibodies and evidence ...

Already a member?

Enter your email to keep reading.


OR